3D Printed Implants for the Defect Reconstruction in Patients With Chest Wall Tumors
Launched by BLOKHIN'S RUSSIAN CANCER RESEARCH CENTER · Sep 15, 2021
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the use of 3D printed titanium implants to help reconstruct the chest wall in patients who have tumors in that area. The goal is to create personalized implants that fit perfectly into the space left after removing the tumor. This process starts with a detailed CT scan, followed by the creation of a model that matches the patient's unique anatomy. Using advanced 3D printing technology, researchers aim to improve the surgical outcome by making sure the implant closely resembles the original shape of the chest wall, which can help reduce complications and speed up recovery.
To participate in this trial, individuals must be adults aged 65 and older who have specific types of tumors affecting the ribs, sternum, or clavicle, including both malignant (cancerous) and benign (non-cancerous) tumors. They should not have distant metastases (cancer spread to other parts of the body) and must be able to give informed consent. If eligible, participants can expect to undergo a surgical procedure with a recovery period of 15 to 30 days. This innovative approach not only aims to improve physical outcomes but also enhances the overall quality of life for patients facing chest wall tumors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Malignant neoplasm of ribs, sternum and clavicle
- • Malignant neoplasm of the connective and soft tissues of the chest
- • Neoplasm of uncertain or unknown nature of ribs, sternum and collarbone
- • Benign neoplasm of ribs, sternum and collarbone
- • Tumor lesions of the chest wall of any localization, malignant and benign, as well as of an uncertain or unknown nature
- • For malignant tumors: Grade 1-3
- • Lack of distant metastases
- • Signed informed consent
- Exclusion Criteria:
- • Children, women during pregnancy, childbirth, women during breastfeeding.
- • Military personnel, with the exception of contract military personnel.
- • Persons with mental disorders.
- • Persons detained, taken into custody, serving a sentence in the form of restriction of freedom, arrest, imprisonment or administrative arrest.
- • Patients with distant metastases (except for a solitary focus in the chest wall without other manifestations of the disease)
- • Inoperable tumor
- • The presence of another malignant tumor at the time of examination
- • ECOG 4
- • Having an active or chronic fungal / bacterial / viral infection
- • Uncontrolled chronic diseases of the liver, kidneys in the acute stage
- • Presence of metastases
About Blokhin's Russian Cancer Research Center
Blokhin's Russian Cancer Research Center is a leading institution dedicated to advancing cancer research and treatment in Russia and beyond. Established with a focus on innovative oncology solutions, the center integrates cutting-edge scientific inquiry with clinical application, aiming to improve patient outcomes through novel therapeutic approaches. With a multidisciplinary team of experts, the center fosters collaboration in the fields of clinical trials, epidemiology, and molecular biology, contributing significantly to the global fight against cancer. Its commitment to excellence in research and patient care positions Blokhin's Russian Cancer Research Center at the forefront of oncology advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Patients applied
Trial Officials
Aslan Valiev, PhD
Principal Investigator
N.N. Blokhin NMRCO
Pavel Kononets, PhD
Principal Investigator
N.N. Blokhin NMRCO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials